Fortini

DUAL STRATEGY PLAYBOOK

GROWTH CATEGORY

2025



Helping kids bounce back

Objective

The objective of this playbook is to help markets build / increase penetration in Growth category by implementing **Dual Strategy (DS).**

It will provide understanding on what DS is, why it is needed and how each market can leverage both global & local assets to maximize its' growth.

Lastly, it should inspire new geos on how they could sustainably build Growth business, while keeping patient-centricity in mind & differentiating vs. competition .



Fortini

TABLE OF CONTENT

01 MAXIMIZING PENETRATION IN GLOBAL GROWTH CATEGORY CONTEXT

02 DUAL STRATEGY FUNDAMENTALS

03 WHERE TO PLAY?

04 HOW TO PLAY?

05 HOW TO WIN?

06 BEST PRACTICE: INDONESIA CASE



Fortini


01

MAXIMIZING PENETRATION IN GLOBAL GROWTH CATEGORY CONTEXT



Fortini

GLOBAL MALNUTRITION PREVALENCE IS HIGH: 1 IN 4 CHILDREN BELOW 14 YO IS ESTIMATED TO BE IMPACTED OR AT RISK




Number of children 0-10 y.o. (millions)

	US	LATAM	EUROPE	CHINA	MENA	ISEA	ANZ	TTL
FG	0.4	22	1	26	107	33	0.03	189
G&EC	10	70	15	67	53	74	1	290
TTL	10	92	16	93	160	107	1	479

*Number of children 0-10 in millions, internal estimations based on total reported number of children and prevalence of FG, G&EC extracted from Growth Opportunity sizing research by FiftyFive Five, Mar'21


HOWEVER, CURRENT CATEGORY PENETRATION IS VERY LOW ACROSS THE GLOBE, WITH ONLY ~23% ON AVG OF KIDS ACTUALLY RECEIVING NUTRITIONAL SUPPORT (DANONE, NESTLE, ABOTT COMBINED)



Source: FiftyFive Five report 'Growth opportunity sizing', March 2021

GROWTH CATEGORY CONTEXT DEFFERS A LOT ACROSS REGIONS & IS INFLUENCED BY VARIOUS FACTORS: SOCIO-ECONOMICS, RX SYSTEM, TAs PREVALENCE, ETC

World disposable income per capita by region*



45K eur*

- Diverse socio-economic status
- Complex RX system, mostly self-paid
- Various TAs prevalent (FTT, CHD, ADHD, etc)

20K eur*

- High socio-economic status
- RX
- Various TAs prevalent (CP, ADHD, IBD, Onco, etc)

4.5K eur*

- Diverse socio-economic status
- RX vs. self-paid
- Stunting most prevalent

10K eur*

- Mid-high socio-economic status
- Completely self-paid
- Various TAs prevalent (CHD, ADHD, Onco, etc)

- Mid-low socio-economic status
- Self-paid
- Various TAs prevalent (CHD, ADHD, Onco, etc)

1.5K eur*

- Very low socio-economic status
- Completely self-paid
- Stunting most prevalent

5K eur*


- Very low socio-economic status
- Self-paid, RX starting
- Stunting most prevalent

13K eur*

- Mid-low socio-economic status
- RX & self-paid
- Various TAs prevalent (CHD, ADHD, Onco, etc)

*Source: A_A18_r_230822.081459.pdf


THESE FACTORS ARE INFLUENCING THE WAY OUR CATEGORY IS SHAPED ACROSS THE GLOBE IN TERMS OF PORTFOLIO, BUSINESS MODEL, BRANDS AND MUCH MORE



THAT'S WHY WE ARE TRYING TO LOOK AT MALNUTRITION AS A SPECTRUM, FROM MORE TO LESS SEVERE CASES, TO BE ABLE TO ADDRESS ALL RELEVANT NEEDS ACROSS THE GLOBE


FALTERING GROWTH

Z SCORE
Meets criteria for
Faltering Growth e.g. ≤ -2






80% of our business today



100-150M KIDS

GROWTH CHALLENGES

Z SCORE
cause for concern
e.g. -1 to –2






20% of our business today

300-450M KIDS

EATING CHALLENGES

Z SCORE
may be at risk
e.g. -1






SEVERE — MODERATE — MILD

HOSPITAL — HCP ROLE

HOME — PARENTAL ROLE

OUR COMPETITORS: PEDIASURE GLOBALLY WITH ONE-SIZE-FITS-ALL IN G&EC SPACE. NESTLE MOSTLY IN EU WITH FALTERING GROWTH, HOWEVER EXPANDING TO G&EC AS WELL



In order to **win**, we need to play smart: with right portfolio, in right channels, at right prices, while leveraging both our **global & local assets**



Fortini

02

DUAL STRATEGY (DS) FUNDAMENTALS



Fortini

What is DS?

DS is a way of building / increasing **category penetration** by using two different value propositions in the same market.

This is done by **diversifying** target audiences, portfolios, price positioning, channels, but also business models, to make sure we offer **relevant** solutions, tailored to each region's need.



KEY PILLARS OF DS

1. Product
2. Channel & Business model
3. Price
4. Brand & Communication
5. TAs



KEY PILLARS OF DS

1. Product -> What are different products & services that we could offer?
2. Channel & Business model -> RX vs. Self-paid: which channels are most relevant for which portfolio?
3. Price: Premium vs. Affordable: what makes sense in which part of the world?
4. Brand & Communication -> Which brand architecture are we using & how are we communicating with our patients & HCPs?
5. TAs -> What type of patients are we targeting with each portfolio to make sure that different needs are met?



03

WHERE TO PLAY?



Fortini

HOW TO DEFINE WHERE TO PLAY?

01
UNDERSTANDING YOUR CONTEXT

- Government policies & health system
- Socio-economics
- Geo-politics
- Population profile (disposable income, education, urbanism, etc)

02
SCOPING OPPORTUNITIES

- Prevalence of malnutrition
- Penetration
- Key TAs identification
- Competitive landscape
- SOP calculation

03
LEVERAGING ASSETS

- Indonesia best practice
- Global data



04

HOW TO PLAY?



Fortini

HOW TO DEFINE HOW TO PLAY?

01
UNDERSTANDING MARKET MATURITY

- Which cluster are you in?
- What are the key questions you need to answer?


02
UNDERSTANDING BUSINESS MODEL

- Key stakeholders mapping (HCPs vs. parents)
- Journey
- Key point of interception identification (initiation / penetration adherence, etc)
- Channels

03
LEVERAGING ASSETS

- Indonesia best practice
- Available portfolio*
- Price positioning (premium vs. affordable)
- Brand architecture (global vs. local)

*Click to consult Glonal Product Booklet 2.0



Fortini

THERE ARE 3 MARKETS CLUSTERS:

01 NEWCOMERS
Markets with no category developed


The Philippines


LATAM new geos


Africa


India


MENA new geos


Korea

KEY QUESTION

Which approach makes more sense for you to start the category?

02 BUILDERS
Markets with developed category but no DBS


Europe


US


Turkey


LATAM


China


Australia & NZ


MENA

KEY QUESTION

What are key opportunities & barriers to start thinking DBS?

03 FIGHTERS
Markets with DBS


Indonesia


SEA

KEY QUESTION

How do you strengthen DBS to accelerate penetration?

01 NEWCOMERS
Markets with no category developed


The Philippines


LATAM new geos


Africa


India


MENA new geos


Korea

KEY QUESTION

Which approach makes more sense for you to start the category?

Questions to assess:

1. What is the population's socio-economic outline in your market?
2. Is there RX system in place?
3. What are the key demand drivers?
4. What is the most prevalent TA?
5. What are the most developed channels?

02 BUILDERS

Markets with developed category but no DBS


Europe


US


Turkey


LATAM


China


Australia & NZ


MENA


KEY QUESTION

What are key opportunities & barriers to start thinking DBS?

Questions to assess:

1. What is the population's socio-economic outline in your market?
2. Is there RX system in place?
3. What are the most important channels?
4. How mature is your portfolio?
5. What is the most prevalent TA?
6. Would you benefit from an affordable solution?
   a) If no – why?
   b) If yes - What are the key opportunities & challenges you see?
5. What kind of brand architecture would you implement?
6. What is the most relevant TA you would target?

03 FIGHTERS
Markets with DBS



Indonesia



SEA

KEY QUESTION

How do you strengthen DBS to accelerate penetration?

Questions to assess:

What do you need to be able to further differentiate your VPs?
Think thru key pillars of DBS:

- Product
- Channel & Business model
- Price
- Brand & Comms
- TAs

05

HOW TO WIN?



Fortini

HOW TO DEFINE HOW TO WIN?

01
SHAPING PLANS

- Portfolio (launches)*
- Pricing strategy
- Brand architecture
- Communication & activation plans**

02
LEVERAGING ASSETS

- Indonesia best practice
- KPIs to measure

03
MAPPING RESOURCES

- Investment prioritization
- A&P
- People



*Click to consult Glonal Product Booklet 2.0
** Click to access Fortini brand universe platform with our BBI toolkit

06

BEST PRACTICE: INDONESIA




Fortini

WHERE TO PLAY?

MALNUTRITION IS AMONG TOP 5 CHILDREN HEALTH ISSUES IN INDONESIA AND ALIGNED WITH GOVERNMENT AGENDA, STUNTING IS STILL NATIONAL PRIORITY.

The Incident of Indonesian Children Health Issues in 2023[1]




Government aimed to reduce to 14% in 2024



Source: 1 Riskesdas 2023; 2 BAT Kantar Non-Breastfeeding rate 62%; 3 70% eligible to use FSMP in Stunting National Guideline 2024; 4 SES A&B 27%, C&D 73%, AWOP Premium :7kg AWOP Mainstream 6kg, LoT: 2 months

WHERE TO PLAY?

INDONESIA: THE OPPORTUNITY TO ADDRESS MALNUTRITION AND STUNTING. HUGE HEADROOM TO PENETRATE CATEGORY AND INCREASE USER BASE (11% in 2023)



Source: 1 BAT Kantar Non-Breastfeeding rate 62%; 2 Riskesdas 2023; 3 70% eligible to use FSMP in Stunting National Guideline 2024; 4 IQVIA Medical Audit 2023

WHERE TO PLAY?

IN NATIONAL GUIDELINE, FSMP ROLE IS ONLY ELIGIBLE IN HOSPITAL WITH RECOMMENDATION FROM PEDS AND ONLY CAN BE PURCHASED IN MEDICAL CHANNEL

Indonesia National Stunting Guideline - MoH

Measurement on weight and height

Normal Baby
Supplementary Feeding with Local Food

Weight Faltering[1]
Core Milk for 1 week



Severely Wasted[2]
F75/F100 for 1 week



Stunting[3]
Final diagnosed by GP

No Adequate weight increment + Red flags
1 WHZ/ WAZ <-2SD; 2 WHZ <-3; 3 HAZ <-2



Posyandu
(1st Tier Healthcare Facility)


GP+Midwives in Puskesmas
(2nd Tier Healthcare Facility)

Peds in Hospital
(3rd Tier Healthcare Facility)

WHERE TO PLAY?

AND BEFORE 2022, FSMP MARKET IS DRIVEN BY THE PREMIUM PLAYER ADDRESSING MOSTLY SES A & B, WHILE 75% OF INDONESIAN ARE SES C AND D

FG Competitor Landscape based on Gross Sales and Price in 2022



WHERE TO PLAY?







3 Main underlying problems:

LACK OF AWARENESS:
A lot of myth stunting

LOW SCREENING:
Unskilled HCP in primary health care

LIMITED ACCESSIBILITY:
Access to HCF

HOW TO PLAY?

... THATS WHY WE AIMED TO UNLOCK FG GROWTH THROUGH DUAL STRATEGY



With **SGM Gain** as the **trusted solution for everyday growth** support and **Infatrini / NutriniDrink formulas for advanced needs**, we are well-positioned to drive sustainable, double-digit growth in FSMP while ensuring no child is left behind.





HOW TO PLAY?

WHAT DOES THAT MEAN FROM DUAL STRATEGY PERSPECTIVE?

POINT OF ENTRY	PRODUCT	CHANNEL	PRICE	BRAND	COMMS

CONGENITAL HEART DISEASE

3.7 Million Children Worldwide
(50% Malnourished)






Hygiene factors
+
Superiority
(GOS:FOS)
+
Services
(Growth tracker, Academy 3)



SELF-PAY
(Private) hospitals



PREMIUM

NUTRICIA Infatrini

NUTRICIA Nutrinidrink



Tailored towards hospitals
&
more affluent consumers

STUNTING

149 Million Children Worldwide
(100% Malnourished)






Key functional
deliverables
(hygiene factors)



RX
Community /
primary care



AFFORDABLE

SGM Anonda Gain 100

SGM Eksplor Gain Optigrow



Tailored towards community
&
less affluent consumers

HOW TO PLAY?

WE SEE ABUNDANT OPPORTUNITIES TO ACTIVATE ACCESSIBILITY, SCREENING & DIAGNOSIS AND AWARENESS

4 M

2.8 M
FSMP Eligible (70%)[1]

1 M
37% Screened & Diagnosed[2]

103 K
10% NDF Rx[3]

82 K
80% Compliance[4]

1 Initiation — 2 — 3 — 4 Extending the journey

Indonesian Stunted Journey

3 Awareness (Origination)

Key Drivers:
- Moms care to children growth & development

Key Barriers:
- Moms know the word stunting but not the manifestation
- Moms didn't aware of FSMP brands

2 Screening & Diagnosis

Key Drivers:
- HCPs are open for screening tool

Key Barriers:
- Wide coverage of HCPs and multisectoral touchpoint

Access to Treatment

10% HCP treatment using FSMP; 90% Core IMF

1a Private Market

Key Drivers:
- Clinically proven
- In national guideline

Key Barriers:
- Not all peds are familiar with Stunting Guideline

1b Reimbursement Market

Key Drivers:
- Stunting is national priority agenda

Key Barrier:
- 1st line treatment with local food & biscuits

Adherence

Consumer Barriers[3]:
- Taste
- Price
- Availability in retail channel
- No perceived as impactful for child's growth

HCP influence[3]

- Pediatrician (52%)
- Midwives (56%)
- General Practitioner (13%)
- Other HCPs (9%)

*Dinkes: District of MoH

Ref: 1. SKI 2023; 2. ACS 2023; 3. Purple Study (IQVIA) 2024; 4. Devaera et al. PGHN, 2018

HOW TO PLAY?

OUR ROUTE TO MARKET FOR FSMP LAYS ON 2 BUSINESS MODEL, WHERE TENDER CONTRIBUTES TO 25% OF SGM GAIN VOLUME

COMMERCIAL (75%)

Hospital/ Peds Engagement in 2nd and 3rd Tier Hospital



Product Scope:
Infatrini, Nutrinidrink (Private A Hospital)
SGM Gain 100 + Optigrow (Public and Private B HOS)

TENDER (25%)

Local Health (Dinkes) Engagement in 1st Tier HCF (Puskesmas)



Product Scope:
SGM Gain 100
SGM Gain Optigrow

HOW TO PLAY?

THE OBJECTIVE OF 3LM IS TO DRIVE SCREENING & DIAGNOSIS AS AN END-TO-END JOURNEY -> FROM SCREENING TO CONVERSION ACTIVATION

AWARENESS

Education

Stunting education directly to the HCP, Gov. Stakeholder and Moms

CONSIDERATION

Screening Day

Screening and Diagnosis to fully detect the symptoms

CONVERSION



Sample

To solve the stunting issue and increase first trial

Helping kids bounce back

HOW TO PLAY?

THE ONLY ONE WITH IRON-C AND SPECIALLY FORMULATED 1KCAL/ML THAT ARE CLINICALLY PROVEN FOR CATCH UP GROWTH

SGM ANANDA GAIN 100 & SGM EKSPLOR GAIN OPTIGROW

Nutrisi Kejar Tumbuh
- Energi 100 kkal/100 mL
- Protein 10,65% En

Nutrisi untuk Dukung Perkembangan Otak
- AA (Omega-6), DHA (Omega-3), IronC

Bebas Sukrosa





TERBUKTI DUKUNG KEJAR TUMBUH KLINIS

0 - 12 Bulan

> 1 Tahun

Nutrisi Kejar Tumbuh
- Energi 100 kkal/100 mL
- Protein 9,4% En

Nutrisi untuk perkembangan kognitif
- PRO-GRESS MAXX dengan IronC, kandungan DHA (Omega-3), AA (Omega-6) untuk mendukung perkembangan otak

Rasa Enak
- Rasa disukai oleh 9 dari 10 Anak (Berdasarkan Sensory Test pada 129 Anak)

*IronC (ratio Zat Besi dan Vitamin C 1:2) untuk bantu anak siap belajar dan siap untuk maju

ASI ADALAH YANG TERBAIK

Penggunaan Formula Bayi hanya jika ada indikasi medis dan atas rekomendasi Tenaga Kesehatan. Hanya untuk Kalangan Medis dan dilarang untuk disebarluaskan ke pihak lain.

HOW TO PLAY?

THE ONLY ONE WITH IRON-C: RIGHT COMBINATION OF IRON & VITAMIN C SINCE IRON DEFICIENCY AS ONE OF THE FALTERING GROWTH RISK FACTOR

Iron Deficiency

↓ Reducing Hemoglobin

↓ Slower metabolism from lack of oxygen

Untreated growth faltering

Stunting


SGM, the only one with IronC to support 2X Iron absorption




HOW TO PLAY?

TO IMPROVE IMAGERIES AND GAIN BOFC, WE ROLL OUT NEWEST CLINICAL STUDY FOR SGM GAIN OPTIGROW

- Lead by Indonesian Pediatrician KOL, study was conducted in weight faltering Indonesian children 1- 5 year. Intervention: SGM Gain Optigrow 400 kkal / day for 90 days & parent dietary counseling.
- In Q2 2024, we will highlight new result for SGM Gain 100





HOW TO PLAY?


SGM
GAIN
(Gerakan Anak Indonesia)
Bebas Stunting
IronC*
PRO-GRESS MAXX


SGM Gain dengan Fortifikasi IronC*
Dapat Membantu Untuk Mencegah Hambatan Pertumbuhan
Kekurangan zat besi pada anak dapat menyebabkan Faltering growth
Kekurangan zat besi
↓ Kadar Hb dan sel darah merah
↓ Kadar oksigen tubuh
↓ Metabolisme pada masa kritis pertumbuhan
Faltering Growth
IronC (Vitamin C dan zat besi 2:1) lebih mudah diserap tubuh dan mempercepat kejar tumbuh dibanding suplemen zat besi biasa
Vitamin C dapat mereduksi ion besi Fe3+ dari makanan menjadi Fe2+ yang mudah diserap oleh usus
Vitamin C dan Fe2+ dapat membentuk kompleks kimiawi yang mudah diabsorbsi usus
Referensi
ASI adalah yang Terbaik
Hanya untuk Kalangan Medis


SGM Gain dengan Rasa yang Enak
SGM Gain memiliki rasa yang disukai oleh 9 dari 10 anak
*Berdasarkan hasil uji sensorik pada 129 anak
Rasa yang enak akan mudah diterima oleh anak-anak sehingga meningkatkan kepatuhan terhadap produk dan konsumsi yang konsisten hingga target pertumbuhan tercapai
ASI adalah yang Terbaik
Hanya untuk Kalangan Medis


SGM EKSPLOR GAIN OPTIGROW dengan IronC*
Formula Tinggi Kalori 100kcal/100ml untuk Bantu Kejar Tumbuh
Anak > 1 Tahun dengan Risiko gagal tumbuh, gizi kurang dan/atau gizi buruk
SGM
Eksplor Gain Optigrow
IronC*
1+
Vanila
400g
Nutrisi Kejar Tumbuh
• Energi 100 kcal/100 ml
• Protein 9.4% En
Nutrisi untuk Perkembangan Kognitif
• PRO-GRESS MAXX dengan IronC, kandungan DHA (Omega-3), AA (Omega-6) untuk mendukung perkembangan otak
Osmolalitas
• 369 mOsmol/kg H2O (angka rekomendasi BPOM max 700 mOsmol/kg H2O)
Rasa Enak
• Rasa disukai oleh 9 dari 10 Anak (berdasarkan sensory test pada 129 anak)
Takaran Saji
• 220 ml SGM Eksplor Gain Optigrow (±220 kkal) = 175 ml air + 8 sendok takar
• 1 sendok takar = 8 g = ±36.7 kkal
*IronC (ratio Zat Besi dan Vitamin C 1:2) untuk bantu anak siap belajar dan siap untuk maju
ASI adalah yang Terbaik
Hanya untuk Kalangan Medis


Lakukan
3 Langkah
MAJU
Mengukur
tinggi dan berat
AJak konsultasi
ke dokter
Upayakan Beri
Nutrisi Teruji Klinis

HOW TO PLAY?

THE OFFLINE SCREENING THROUGH GMBS MOBI AND ONSITE DINKES WITH FOCUS ON AREAS WITH HIGH STUNTING RATE





On-site screening

MOBI screening



HOW TO PLAY?

ALODOKTER

Online Consumer Screening



ALODOKTER

Online PEDS Consultation



SGM MOBI



OFFLINE DINKES

NutriGain

NUTRICIA PROFESSIONAL

GENERASI MAJU BEBAS STUNTING

Microsite (House of GMBS) “1,000,000”

Alfamart

APOTEK K24 Sobat Sehat Kita-Kita

3rd parties CSR program



Mombassadors With Village Cadres

HOW TO PLAY?

WE'RE AIMING TO GET REIMBURSEMENT FOR FG PORTFOLIO FROM NATIONAL AND LOCAL GOVERNMENT THRU MARKET ACCESS STRATEGIES

NATIONAL REIMBURSEMENT (VIA UNIVERSAL HEALTH COVERAGE/FORNAS)

Pioneering FSMP Category Reimbursable for the 1st ever in Indonesia (MOH Decree (KMK 2197/2023)

Cracking the opportunity for FSMP Premature and Galactosemia



For the **1st time ever in Indonesia HEOR history,** Health Economic (CUA) analysis with **nutrition intervention** (using SGM Eksplor Optigrow) has been **presented as Poster presentation** in ISPOR Europe and awarded for top 5% poster

LOCAL TENDER REIMBURSEMENT (VIA LOCAL HEALTH AUTHORITY PROGRAM)

Reimbursement in

249

Local Health Authority



Volume

602 Ton

2024-YTD 2025

Value

6.1 Meur

2024-YTD 2025

Growth

+9%

FY'25 vs FY'24

Reach Children

70K


*Source : Blitz FY'24 - April '25
1 Euro = IDR 16.960

HOW TO WIN?

AFFORDABLE SOLUTION LAUNCH SUCCESSFUL WITH GREAT RESULTS. SGM GAIN IS WELL ACCEPTED BY HCPS AND ANSWERS MOMS NEEDS

Strong TS Performance

Volume CAGR
+236%



Strong Market Share

In Government Hospital* -
HCP Tracking Q2'23

+1,500
bps

(Q2'23 vs 21)

Occupied 20% FG Market Share

Gain Believe in HCPs


No. #1
Peds
Reco

In Government Hospital* - HCP Tracking Q2'23
(1.5 year after launching)

HOW TO WIN?

WITH DUAL BRAND STRATEGY, WE ARE ABLE TO ACCELERATE CATEGORY PENETRATION

Faltering Growth Performance 2019-2024 (in mE)



CAGR VOL
+53%

CAGR VAL
+41%


Market Share
(MED AUDIT Q4 '24)
71%

Source: Demand 2024


HOW TO WIN?

AND PROVEN FROM HCP DEMAND CREATION FROM FG BRANDS, SUSTAINABLE RECO FROM SGM GAIN AND INCREASE RECCOMENDATION OF NUTRINIDRINK

Nutrinidrink



SGM Gain Opti




Source: Kantar HCP Tracking : most often recommended brand among Peds

HOW TO WIN?

WHY HAVE WE WIN SO FAR – MS 71%*

GOVERNMENT'S FOCUS ON HIGH STUNTING RATE SINCE 2019





From President Jokowi until Prabowo, Stunting is still high in the government agenda
The question is only How.

CLEAR PRODUCT POSITIONING TAILORED TO CHILDREN NEEDS



DANONE'S RTM CAPABILITIES

- **The Right Hospitals and Peds**

118 Reps
2.3k Hospitals
3.8k Peds
Penetration 81%

- **The Right Pharmacies**

9K Pharmacies
11K Pharmacists

- **Strong Market Access Team**

1 NOM + 12 FOMs
552 Provincial/City MOH Bodies

*Source: Medical Audit Q4'24

CONTACTS

If you have any questions, please get in touch with Global, Regional & Local Indonesia Growth teams.



Jelena Mitrovic
Global growth strategy lead
jelena.mitrovic@danone.com



Anthony Lee
Global growth category director
anthony.lee@danone.com



Raghav Gupta
Regional SN new market entry strategy director
raghav.gupta@danone.com



Yosua Yosua
Indonesia HN marketing lead FSMP
yosua.yosua@danone.com

Fortini

Fortini

THANK YOU



Helping kids bounce back